A multicenter, non-comparative study to evaluate the efficacy and safety of fixed- dose olmesartan/amlodipine in hypertensive patients
Creators
- Abdullah Al Shafi Majumder1
- Mohammad Ullah2
- Md. Toufiqur Rahman2
- AKM Monowarul Islam2
- Md Alimur Reza3
- Khondokar Asaduzzaman2
- SM Quamrul Huq2
- Abu Zahid Bosunia2
- Durul Hoda2
- Solaiman Mia2
- Moniruzzaman2
- Goutam Kumar Acherjya2
- Abdur Rahim2
- Anisul Awa l2
- Ashraf Uddin Chowdhury2
- Azizur Rahman Roman2
- Dipankar Chandra Nag2
- Durba Halder2
- Gobinda Kanti Paul2
- K. M. Kamal2
- Md. Abul Khair2
- Md. Ajmirul Hoque Sarkar2
- Md. Fakhrul Islam Juwel2
- Md. Khalequzzaman2
- Md. Mahbubur Rahman2
- Md. Mizanur Rahman2
- Md. Mushfequr Rahman Khan2
- Md. Nuruddin Tareq2
- Md. Rayhan Masum Mandal2
- Md. Saiful Islam2
- Md. Sk. Mamun2
- Md. Zillur Rahman2
- Mezbah Uddin Ahmed2
- Mir Md. Muntaquim Haider2
- Moeen Uddin Ahmed2
- Mohammad Nasir Uddin2
- Molla Md Iftekhar Hossain2
- Nishit Kumar Majumder2
- Nur Alam2
- Prashanto Kumar Swarnoker2
- Rajesh Kumar Gosh2
- Rajib Gosh2
- Ranjit C. Khan2
- Rashid Ahmed2
- Sahela Nasrin2
- Shahana Zaman2
- Shahriar Kabir2
- Sheikh Marufuzzaman2
- Shishir Kumar Basak2
- Sirajur Rahman Sarwar2
- Solaiman Hossain2
- Solaiman Tanvir2
- Sufia Jannat2
- Sujit Kumar Chanda2
- Swadesh Kumar Chakrovortty2
- Syed Nasir Uddin2
- Zahiruddin Mahmud Ilias2
- Miah Mohammad Jamsidul Hassan3
- 1. President of Cardiology Study Group, Bangladesh.
- 2. Member of Cardiology Study Group, Bangladesh
- 3. Department of Medical Affairs, Beximco Pharmaceuticals Ltd, Bangladesh.
Description
Background: Uncontrolled blood pressure (BP) is a major healthcare issue and responsible for high risk of cardiovascular disease (CVD) mortality and morbidity. Physicians of Bangladesh had been using amlodipine and Olmesartan combination for a long period of time but have very limited evidence-based information regarding the efficacy and safety of this combination. The aim of this study was to evaluate the efficacy and safety of fixed dose combination of olmesartan/amlodipine in hypertensive patients.
Methods: This open-label, non-randomized, non-comparative observational study was conducted in different centers of Bangladesh during the period from January 2020 to November 2020. In total 443 Bangladeshi adult patients with hypertension were selected as the study population. Proper written consent was taken from all the participants before collecting data. Inter-group differences in the baseline characteristics were compared using analysis of variance (ANOVA). Two-tailed p-values of less than 0.05 were considered to be statistically significant. Statistical analyses were conducted by using SPSS for Windows, version 25 (SPSS Inc., Chicago, IL, USA).
Results: Among all the participants, more than 70% were above 46 years of age and 55% were male. More than 60% of them were either overweight or obese. Among them, dyslipidemia, diabetes, and Chronic renal failure (CRF) was found among 14.22%, 28.44%, and 4.29% participants respectively Mean systolic (SBP) and diastolic blood pressures (DBP) were reduced to 36.61 and 18.69 mm of Hg respectively after 12 weeks of therapy. Besides these, the targeted SBP was achieved among 92% and targeted DBP was achieved among 98.3% of participants after 12 weeks. Achievement of BP goal in respect to Body mass index (BMI) of the patient (P-value 0.019), family history of hypertension (P-value 0.028), and dose of the drug in initial visit (P-value 0.001) was found statistically significant. There was no discontinuation of study medication due to intolerance or adverse events.
Conclusion: Olmesartan/Amlodipine is an effective combination for reducing the blood pressure along with achievement of BP goal. Future studies on Olmesartan/Amlodipine in Bangladesh could be conducted with a longer treatment duration to examine the maintenance of effect and long-term safety.
Files
WJARR-2022-0506.pdf
Files
(1.2 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:c1d960daa2623f529e91be46045218c2
|
1.2 MB | Preview Download |